The global Enzyme-Linked Immunosorbent Assay (ELISA) market is projected to grow at a CAGR of 6.31%, increasing from US$28.815 billion in 2020 to US$44.222 billion in 2027.
ELISA (enzyme-linked immunosorbent assay) or enzyme immunoassay (EIA) is a plate-based assay technique designed for detecting and quantifying substances such as peptides, proteins, antibodies, and hormones. ELISA is often used as a screening tool before further in-depth tests are ordered. Reactants of the ELISA are immobilized to the microplate surface making it easy to separate bound from non-bound material during the assay making it a powerful tool for measuring specific analytes within a crude preparation. The common diagnostic applications of ELISA are HIV infection, pregnancy tests, detection of proteins, etc. The ELISA market is expected to show robust growth during the forecast period. The growth may be attributed to the rising incidence of infectious and chronic diseases which require ELISA as a cost-effective diagnostic tool. However, stringent regulatory requirements, as well as unfavourable reimbursement policies pertaining to ELISA, might hamper the growth of the market during the given time frame.
The growing incidence of infectious diseases such as HIV, Hepatitis, malaria, Dengue and influenza, among various other infections is one of the major factors driving the growth of the market. According to the WHO, there were approximately 38.4 million people across the globe living with HIV at the end of 2021, and over two-thirds of them were in the African region. Also, the same source stated that dengue fever is said to be one of the top ten threats to global health. There has been an increase of about 3000% in global dengue incidences over the past 50 years. According to WHO, in 2019, Over 296 million people across the globe live with Hepatitis B infection. Such increasing incidence of infectious diseases is expected to increase the demand for diagnosis. The increased usage of advanced diagnostic tools such as enzyme-linked immunosorbent assays for screening these diseases is expected to attribute to the growth of the market.
Further, the rise in the geriatric population who are at risk of developing various infections, and chronic disorders, and are in need of regular diagnosis across the globe is also expected to drive the growth of the market. The NCBI (National Centre for Biotechnology for Information) in 2021, reported that potentially serious infections are quite common in older patients than in younger ones. Such factors are thus projected to significantly increase the demand for the enzyme-linked immunosorbent assay market, thereby augmenting the growth of the market.
Disease diagnosis segment holds a substantial share of the market
The disease diagnosis segment has been projected to hold a significant share due to the increasing application of enzyme-linked immunosorbent assay tests in the diagnosis of tumour antigens. According to the WHO in 2022, Non-communicable diseases were reported to kill about 41 million people annually, contributing to 71% of all deaths globally. These incidences have increased the demand for effective diagnostic tools like ELISA for timely diagnosis to prevent deaths. Further, the Global cancer observatory in 2020, stated that an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths occurred globally. This increase in cancer cases across the globe thus drives the demand for ELISA as it serves as an effective tool in measuring the antigens. Furthermore, according to the Nature Scientific report in 2020, the Enzyme-Linked Immunosorbent Assay can be used for the detection of prostate cancer antigens and breast cancer antigens as well. Such cost-effective diagnosis along with the accuracy of detection in antigens are expected to increase the demand for ELISA and propel the growth of the market in the analysed period.
North America is Expected to Hold a Significant Share in the Market
The US is likely to command the global market due to the rapid adoption of technological advancements in diagnostic tools like ELISA. The robust growth of the demand for Enzyme-linked Immunosorbent Assay can be attributed to the rising prevalence of various infectious and chronic diseases among the population of this region. For instance, the CDC (Centre for Disease Control and Prevention) in 2022 stated that about 60% of Americans lived with at least one chronic disease like heart disease and stroke and cancer, among others. Further, the increasing investment in R&D activities and various funding programs for diagnostic purposes is expected to drive the growth of the market in this region. According to the Binder Dijker Otte USA Reports in 2020, companies listed on the biotechnology index increased their R&D spending by 16% on average in 2020 to USD 284.25 million in the US. Also, the Department of Health and Human Services stated in 2021 that they would invest USD 650 million from the American rescue plan to bolster manufacturing capacity for rapid, high-quality diagnostic testing. Thus, all these factors are anticipated to hold the regional market of North America in good stead over the forecasted period.
COVID-19 increased the demand for the Immunoassays like Enzyme-Linked Immunosorbent assays across the globe. This was mainly due to the increase in infection rates, which increased the necessity for effective diagnosis. According to the NCBI Journal in 2020, SARS-CoV-2 can be detected by ELISA with high accuracy. Thus, an increase in the demand for cost-effective and effective diagnoses to get the appropriate treatment drove the growth of the market.
Frequently Asked Questions (FAQs)
Q1. What will be the enzyme-linked immunosorbent assay market size by 2027?
A1. The enzyme-linked immunosorbent assay market is projected to reach a total market size of US$44.222 billion by 2027.
Q2. What is the size of the global enzyme-linked immunosorbent assay (ELISA) market?
A2. Enzyme-Linked Immunosorbent Assay (ELISA) Market was valued at US$28.815 billion in 2020.
Q3. What are the growth prospects for the enzyme-linked immunosorbent assay market?
A3. The global enzyme-linked immunosorbent assay market is projected to grow at a CAGR of 6.31% during the forecast period.
Q4. Which region holds the largest share of the enzyme-linked immunosorbent assay market?
A4. North America is expected to hold a significant share of the enzyme-linked immunosorbent assay market due to the rapid adoption of technological advancements in diagnostic tools like ELISA.
Q5. What factors are anticipated to drive the enzyme-linked immunosorbent assay market growth?
A5. The growing incidence of infectious diseases such as HIV, Hepatitis, malaria, Dengue, and influenza, among various other infections is one of the major factors driving the enzyme-linked immunosorbent assay market growth.
1.1. Market Overview
1.2. Covid-19 Scenario
1.3. Market Definition
1.4. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Driver
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of End-Users
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) MARKET, BY TYPES
5.2. Indirect ELISA
5.3. Sandwich ELISA
5.4. Competitive ELISA
6. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) MARKET, BY APPLICATION
6.2. Food and Beverage
6.3. Vaccine Development
6.6. Drug Monitoring
7. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) MARKET, BY END USERS
7.2. Pharmaceutical Industries
7.3. Hospitals and Clinics
7.4. Diagnostic Centres
8. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) MARKET, BY GEOGRAPHY
8.2. North America
8.2.1. United States
8.3. South America
8.5. Middle East and Africa (MEA)
8.5.1. Saudi Arabia
8.6. Asia Pacific
8.6.5. South Korea
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Emerging Players and Market Lucrativeness
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Vendor Competitiveness Matrix
10. COMPANY PROFILES
10.1. Pestka Biomedical Laboratories, Inc.
10.2. Diaclone SAS
10.3. Thermo Fisher Scientific Inc.
10.4. Azure Biosystems Inc.
10.5. R&D Systems, Inc.
10.6. RayBiotech, Inc.
10.8. BioLegend, Inc.
10.9. Randox Toxicology
10.10. STEMCELL Technologies Inc.
10.11. Genway Biotech, Inc.
Pestka Biomedical Laboratories, Inc.
Thermo Fisher Scientific Inc.
Azure Biosystems Inc.
R&D Systems, Inc.
STEMCELL Technologies Inc.
Genway Biotech, Inc.
All our studies come with 2 months of analyst support.
We are in compliance with the global privacy laws.